Functionalized azamacrocyclic compounds as Ca²⁺ sensitive contrast

agents for MR imaging

<u>Ilgar Mamedov</u>¹, Josef Pfeuffer¹, Nikos K. Logothetis¹, Hermann A. Mayer²

¹Max Planck Institute for Biological Cybernetics, Tuebingen, D, Germany,²Institute for Inorganic Chemistry, University of Tuebingen, Tuebingen, D, Germany

Introduction. The ability to non-invasively observe changes in Ca²⁺ concentration is important for neuroscience. We have therefore developed a series of gadolinium chelate complexes based on DO3A (Scheme 1), which is hypothesized to change relaxivity in magnetic resonance experiments dynamically with Ca²⁺ concentration. Different lengths of the phosphonate side chains are expected to lead to different binding constants of the phosphonate - gadolinium bonds. The latter property can be exploited for fine-tuning the sensitivity of the agent to calcium ion concentration.

Synthesis of ligands and complexes. Ligands were prepared in four steps from Cyclen including alkylation, deprotection and introduction of phosphonate groups

ин ни

NH HN

(Scheme 1). Pure products were obtained as a white powders in total yield 74.2% (**a**), 69.5% (**b**) and 70.3% (**c**). Gadolinium complexes were obtained by treating of the ligands with 1.2 equivalent of GdCl₃ at pH 7.0 -7.5 and 60°C for 18h.

Results and Discussion. MR relaxivity r_1 and r_2 was measured for four concentrations of each macrocyclic compound (0.1, 0.4, 0.7, 1.0 mM) at pH 7.2 in a KMOPS buffer and different concentrations of Ca²⁺. The sensitivity of the contrast agents for changes in Ca²⁺ concentrations increased with the chain length of the phosphonate functions (See Fig.1). Specifically for compound **c** the range of




Figure 1. Dependence of the complexes relaxivity to the Ca²⁺ions concentration

Ca²⁺concentration is compatible with extracellular physiological conditions.

This work was supported by the Max-Planck Society, the Louis-Jeantet Foundation, and the Hertie Foundation